JAHA:替卡格雷在急性心肌梗死中的应用!

2018-06-10 xing.T MedSci原创

由此可见,当前的分析显示出院时给与替卡格雷的数量显著增加,同时使用低剂量阿司匹林的依从性也很高。

替卡格雷是一种与氯吡格雷相比具有更好临床疗效的P2Y12受体抑制剂。然而,与高剂量阿司匹林联合使用时,其疗效会降低。

近日,心血管疾病领域权威杂志JAHA上发表了一篇研究文章,该研究纳入了2013年10月至2014年12月期间的急性冠脉综合征患者(167455例,622个地区)。研究人员评估了处方中P2Y12抑制剂的时间变化趋势,并确定了与出院服用替卡格雷的相关因素。在出院时服用替卡格雷和阿司匹林(21262例)的患者中,研究人员评估了出院时高剂量阿司匹林的时间变化趋势和相关的独立因素。

研究人员发现出院时替卡格雷出现在处方中的频率明显增加,从12%增加到16.7%(P<0.0001)。出院时普拉格雷和氯吡格雷的使用频率减少(分别为15.7%-13.9%和54.2%-51.1%,P<0.0001)。与出院时给与替卡格雷而不是氯吡格雷的处方相关的独立因素包括年龄较小、白种人、在家服用替卡格雷、创伤治疗、医院内再梗死和卒中(P<0.0001),而年龄较大、女性、既往卒中、在家服用替卡格雷和院内脑卒中(P<0.0001)均与出院时首选替卡格雷而不是普拉格雷有关。高剂量阿司匹林用于3.1%的出院时给与替卡格雷的患者。与出院时给与阿司匹林处方相关的独立因素包括在家服用阿司匹林、糖尿病、既往心肌梗死、既往冠状动脉旁路移植术、ST段抬高心肌梗死、心源性休克和地理区域(P=0.01)。

由此可见,当前的分析显示出院时给与替卡格雷的数量显著增加,同时使用低剂量阿司匹林的依从性也很高。

原始出处:

Sukhdeep S. Basra.et al. Ticagrelor Use in Acute Myocardial Infarction: Insights From the National Cardiovascular Data Registry.JAHA.2018. https://doi.org/10.1161/JAHA.117.008125

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1267841, encodeId=3ee7126e84104, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Tue Jun 12 03:38:00 CST 2018, time=2018-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1370697, encodeId=2f5a13e069728, content=<a href='/topic/show?id=691a603409f' target=_blank style='color:#2F92EE;'>#替卡格雷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60340, encryptionId=691a603409f, topicName=替卡格雷)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2fe4321, createdName=lifangping, createdTime=Tue Jun 12 03:38:00 CST 2018, time=2018-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323401, encodeId=f824323401d5, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Mon Jun 11 23:49:59 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323063, encodeId=22fb323063fe, content=好知识值得借鉴!!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59321624668, createdName=zb1235672, createdTime=Sun Jun 10 12:54:13 CST 2018, time=2018-06-10, status=1, ipAttribution=)]
    2018-06-12 zhaohui6731
  2. [GetPortalCommentsPageByObjectIdResponse(id=1267841, encodeId=3ee7126e84104, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Tue Jun 12 03:38:00 CST 2018, time=2018-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1370697, encodeId=2f5a13e069728, content=<a href='/topic/show?id=691a603409f' target=_blank style='color:#2F92EE;'>#替卡格雷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60340, encryptionId=691a603409f, topicName=替卡格雷)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2fe4321, createdName=lifangping, createdTime=Tue Jun 12 03:38:00 CST 2018, time=2018-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323401, encodeId=f824323401d5, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Mon Jun 11 23:49:59 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323063, encodeId=22fb323063fe, content=好知识值得借鉴!!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59321624668, createdName=zb1235672, createdTime=Sun Jun 10 12:54:13 CST 2018, time=2018-06-10, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1267841, encodeId=3ee7126e84104, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Tue Jun 12 03:38:00 CST 2018, time=2018-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1370697, encodeId=2f5a13e069728, content=<a href='/topic/show?id=691a603409f' target=_blank style='color:#2F92EE;'>#替卡格雷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60340, encryptionId=691a603409f, topicName=替卡格雷)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2fe4321, createdName=lifangping, createdTime=Tue Jun 12 03:38:00 CST 2018, time=2018-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323401, encodeId=f824323401d5, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Mon Jun 11 23:49:59 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323063, encodeId=22fb323063fe, content=好知识值得借鉴!!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59321624668, createdName=zb1235672, createdTime=Sun Jun 10 12:54:13 CST 2018, time=2018-06-10, status=1, ipAttribution=)]
    2018-06-11 清风拂面

    谢谢分享学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1267841, encodeId=3ee7126e84104, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Tue Jun 12 03:38:00 CST 2018, time=2018-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1370697, encodeId=2f5a13e069728, content=<a href='/topic/show?id=691a603409f' target=_blank style='color:#2F92EE;'>#替卡格雷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60340, encryptionId=691a603409f, topicName=替卡格雷)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2fe4321, createdName=lifangping, createdTime=Tue Jun 12 03:38:00 CST 2018, time=2018-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323401, encodeId=f824323401d5, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Mon Jun 11 23:49:59 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323063, encodeId=22fb323063fe, content=好知识值得借鉴!!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59321624668, createdName=zb1235672, createdTime=Sun Jun 10 12:54:13 CST 2018, time=2018-06-10, status=1, ipAttribution=)]
    2018-06-10 zb1235672

    好知识值得借鉴!!!!

    0

相关资讯

Int J Cardiol:阿托伐他汀联合替卡格雷防止缺血再灌注诱导的血管内皮功能障碍!

由此可见,慢性阿托伐他汀结合替卡格雷治疗可以预防急性前臂缺血后血管内皮功能障碍。单独服用替卡格雷可减轻内皮依赖性FBF反应损伤,相比于无药物干预的情况。

JAMA:替格瑞洛可提高冠状动脉旁路术患者移植物通畅率

研究认为,对于接受隐静脉移植物移植的冠状动脉旁路术患者,服用替卡格雷可显著提高术后1年移植物通畅率

J Thromb Haemost:替卡格雷治疗的非ST段抬高心肌梗死患者停用阿司匹林后果如何?

由此可见,ACS后早期停用阿司匹林会导致对花生四烯酸的血小板反应性增加,尽管联合有效的P2Y12受体阻滞剂治疗。

JACC:替卡格雷能明显改善多血管冠脉疾病患者预后

心梗(MI)和多血管冠脉疾病(MVD)患者出现反复性冠脉事件的风险大大增高。本研究的目的旨在评估替卡格雷对PEGASUS-TIMI 54临床试验中的MVD患者的有效性和安全性。有1-3年心梗病史的患者被纳入PEGASUS-TIMI 54临床试验,并根据MVD进行分层。评估替卡格雷(60mg或者90mg)对主要心血管不良事件(MACE,心源性死亡、MI和卒中)、冠脉事件(冠脉源性死亡、MI和支架内血

Circ-Cardiovasc Inte:替卡格雷预处理对接受PCI治疗的急性ST段抬高心肌梗死患者无益!

由此可见,接受PCI的ST段抬高心肌梗死患者在导管室给予替卡格雷预处理并没有改善30天全因死亡、心肌梗死和支架内血栓形成复合事件或各个组分的结局。

Heart:不同抗血小板治疗与经皮冠状动脉介入治疗死亡率之间的关系!

由此可见,在89000名接受PCI的STEMI患者队列中,相比于氯吡格雷和替卡格雷,普拉格雷可以显著降低30天和1年死亡率。